Evidence map›Paper›PMID 35413391›Full record

ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2022

Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial.

Ryan Miller, Tess Santangelo, Farnoush Forghani-Arani, Chad Rusthoven, Yingxuan Chen, Edward Castillo, Richard Castillo, Thomas Guerrero, Yevgeniy Vinogradskiy

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Innate [European journal of nuclear medicine and molecular imaging · 2025
    Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ryan MillerThomas Jefferson University, United States. Electronic address: ryan.miller@jefferson.edu.
Tess SantangeloUniversity of Colorado, United States.
Farnoush Forghani-AraniUniversity of Colorado, United States.
Chad RusthovenUniversity of Colorado, United States.
Yingxuan ChenThomas Jefferson University, United States.
Edward CastilloUniversity of Texas, United States.
Richard CastilloEmory University, United States.
Thomas GuerreroBeaumont Health System, United States.
Yevgeniy VinogradskiyThomas Jefferson University, United States.
University of Colorado System · USThomas Jefferson University · USBeaumont Health · USEmory University · US

Funding

Development of a Novel Lung Function Imaging Modality for comprehensive management of lung cancerR01CA236857 · NCI · UNIVERSITY OF COLORADO DENVER · PI CASTILLO, EDWARD, CASTILLO, RICHARD · 2020 to 2025
$2.4M
Quantitative Lung Function Imaging to Reduce Toxicity for patients treated with Radiation and ImmunotherapyUG3CA247605 · NCI · THOMAS JEFFERSON UNIVERSITY · PI CASTILLO, EDWARD, CASTILLO, RICHARD · 2021 to 2022
$664k
NCI NIH HHS R01 CA236857NCI NIH HHS UG3 CA247605
6 · The paper itself

Abstract

The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68-0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyFluorodeoxyglucose F18HumansPositron-Emission TomographyProspective StudiesRadiopharmaceuticalsFluorodeoxyglucose F18RadiopharmaceuticalsCardiac toxicityFunctional imagingLung cancer

Identifiers

PMID35413391
PMCPMC9660739
OpenAlexW4223412037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.